SG10201911963VA - Chimeric receptors to flt3 and methods of use thereof - Google Patents

Chimeric receptors to flt3 and methods of use thereof

Info

Publication number
SG10201911963VA
SG10201911963VA SG10201911963VA SG10201911963VA SG10201911963VA SG 10201911963V A SG10201911963V A SG 10201911963VA SG 10201911963V A SG10201911963V A SG 10201911963VA SG 10201911963V A SG10201911963V A SG 10201911963VA SG 10201911963V A SG10201911963V A SG 10201911963VA
Authority
SG
Singapore
Prior art keywords
flt3
methods
chimeric receptors
chimeric
receptors
Prior art date
Application number
SG10201911963VA
Other languages
English (en)
Inventor
Alice Bakker
Lawren Wu
Tara Arvedson
Jed J Wiltzius
Ruben Alvarez Rodriguez
Original Assignee
Amgen Inc
Kite Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc, Kite Pharma Inc filed Critical Amgen Inc
Publication of SG10201911963VA publication Critical patent/SG10201911963VA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
SG10201911963VA 2016-04-01 2017-03-31 Chimeric receptors to flt3 and methods of use thereof SG10201911963VA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662317219P 2016-04-01 2016-04-01

Publications (1)

Publication Number Publication Date
SG10201911963VA true SG10201911963VA (en) 2020-02-27

Family

ID=58530714

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201808622SA SG11201808622SA (en) 2016-04-01 2017-03-31 Chimeric receptors to flt3 and methods of use thereof
SG10201911963VA SG10201911963VA (en) 2016-04-01 2017-03-31 Chimeric receptors to flt3 and methods of use thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201808622SA SG11201808622SA (en) 2016-04-01 2017-03-31 Chimeric receptors to flt3 and methods of use thereof

Country Status (26)

Country Link
US (2) US20190183931A1 (enrdf_load_stackoverflow)
EP (1) EP3436479A1 (enrdf_load_stackoverflow)
JP (3) JP2019516352A (enrdf_load_stackoverflow)
KR (2) KR102694879B1 (enrdf_load_stackoverflow)
CN (1) CN109641956A (enrdf_load_stackoverflow)
AR (2) AR109626A1 (enrdf_load_stackoverflow)
AU (3) AU2017240801A1 (enrdf_load_stackoverflow)
BR (1) BR112018070187A8 (enrdf_load_stackoverflow)
CA (1) CA3019655A1 (enrdf_load_stackoverflow)
CL (1) CL2018002792A1 (enrdf_load_stackoverflow)
CO (1) CO2018011804A2 (enrdf_load_stackoverflow)
CR (2) CR20180518A (enrdf_load_stackoverflow)
EA (1) EA201892193A1 (enrdf_load_stackoverflow)
IL (2) IL296966A (enrdf_load_stackoverflow)
MA (1) MA44507A (enrdf_load_stackoverflow)
MX (1) MX2023013729A (enrdf_load_stackoverflow)
MY (1) MY201207A (enrdf_load_stackoverflow)
NZ (1) NZ746925A (enrdf_load_stackoverflow)
PE (2) PE20190201A1 (enrdf_load_stackoverflow)
PH (1) PH12018502118B1 (enrdf_load_stackoverflow)
SA (1) SA518400154B1 (enrdf_load_stackoverflow)
SG (2) SG11201808622SA (enrdf_load_stackoverflow)
TN (1) TN2018000337A1 (enrdf_load_stackoverflow)
TW (2) TWI776807B (enrdf_load_stackoverflow)
UA (1) UA128326C2 (enrdf_load_stackoverflow)
WO (1) WO2017173410A1 (enrdf_load_stackoverflow)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201116559D0 (en) 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
US9725710B2 (en) 2014-01-08 2017-08-08 Flodesign Sonics, Inc. Acoustophoresis device with dual acoustophoretic chamber
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
JOP20160086B1 (ar) 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20160198B1 (ar) 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JO3633B1 (ar) 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
CA3013407A1 (en) 2016-03-31 2017-10-05 Janssen Pharmaceuticals, Inc. Substituted indoline derivatives as dengue viral replication inhibitors
CR20180495A (es) 2016-03-31 2018-12-06 Univ Leuven Kath Deribados de indol sustituidos como inhibidores de replicación viral del dengue
WO2017173256A1 (en) * 2016-04-01 2017-10-05 Kite Pharma, Inc. Chimeric antigen and t cell receptors and methods of use
JP7366543B2 (ja) 2016-04-01 2023-10-23 カイト ファーマ インコーポレイテッド Ｂｃｍａ結合分子及びその使用方法
JOP20170069B1 (ar) 2016-04-01 2021-08-17 1 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
SMT202200444T1 (it) 2016-04-01 2023-01-13 Amgen Inc Recettori chimerici e procedimenti di utilizzo degli stessi
AU2017240076A1 (en) 2016-04-01 2018-08-09 Janssen Pharmaceuticals, Inc. Substituted indole compound derivatives as dengue viral replication inhibitors
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
WO2018119279A1 (en) 2016-12-21 2018-06-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies specific for flt3 and uses thereof
JOP20180026A1 (ar) 2017-03-31 2019-01-30 Univ Leuven Kath مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180025B1 (ar) 2017-03-31 2021-08-17 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
LT3630724T (lt) 2017-05-22 2021-08-25 Janssen Pharmaceuticals, Inc. Pakeistieji indolino dariniai, kaip dengės viruso replikacijos inhibitoriai
TWI758480B (zh) 2017-05-22 2022-03-21 美商健生醫藥公司 作為登革熱病毒複製抑制劑之經取代之吲哚啉衍生物（二）
CA3062328A1 (en) 2017-06-02 2018-12-06 Pfizer Inc. Chimeric antigen receptors targeting flt3
CR20200099A (es) 2017-08-03 2020-07-24 Amgen Inc Muteínas de interleucina 21 y métodos de tratamiento
MA50077A (fr) 2017-09-08 2020-07-15 Amgen Inc Inhibiteurs de kras g12c et leurs procédés d'utilisation
JP2019122373A (ja) 2018-01-12 2019-07-25 アムジエン・インコーポレーテツド 抗ｐｄ−１抗体及び治療方法
AU2019240370B2 (en) * 2018-03-23 2024-03-07 Gavish-Galilee Bio Applications Ltd. Genetically reprogrammed Tregs expressing membrane-bound IL-10
MY203383A (en) * 2018-04-10 2024-06-26 Amgen Inc Chimeric receptors to dll3 and methods of use thereof
WO2019197678A1 (en) * 2018-04-13 2019-10-17 Sangamo Therapeutics France Chimeric antigen receptor specific for interleukin-23 receptor
US20220160771A1 (en) * 2019-04-10 2022-05-26 Iulia Diaconu Flt3-specific chimeric antigen receptors and methods of using the same
EP3962527A4 (en) 2019-04-30 2023-11-01 Senti Biosciences, Inc. CHIMERIC RECEPTORS AND METHODS OF USE THEREOF
US20230355765A1 (en) * 2019-12-16 2023-11-09 Washington University Chimeric antigen receptor dendritic cells (car-dcs) and methods of making and using same
JP2023522330A (ja) * 2020-04-17 2023-05-30 シティ・オブ・ホープ Ｆｌｔ３陽性悪性腫瘍を処置するためのｆｌｔ３標的化キメラ抗原受容体改変細胞
CN111808821B (zh) * 2020-06-24 2022-06-14 南方医科大学珠江医院 Flt3-nkg2d双靶点car-t的构建与制备
CA3201115A1 (en) 2020-12-21 2022-06-30 Shanshan LANG Protease-activating cd45-gate car
TW202246517A (zh) * 2021-01-28 2022-12-01 美商異基因治療有限公司 用於轉導免疫細胞之方法
WO2022165233A1 (en) 2021-01-29 2022-08-04 Allogene Therapeutics, Inc. KNOCKDOWN OR KNOCKOUT OF ONE OR MORE OF TAP2, NLRC5, β2m, TRAC, RFX5, RFXAP AND RFXANK TO MITIGATE T CELL RECOGNITION OF ALLOGENEIC CELL PRODUCTS
CN116410315A (zh) * 2021-12-31 2023-07-11 博生吉医药科技(苏州)有限公司 一种新型靶向人flt3的嵌合抗原受体修饰的t细胞的构建及应用
WO2024026445A1 (en) 2022-07-29 2024-02-01 Allogene Therapeutics Inc. Engineered cells with reduced gene expression to mitigate immune cell recognition
WO2025096560A1 (en) 2023-10-30 2025-05-08 Allogene Therapeutics, Inc. Engineered cells

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
ATE87659T1 (de) 1986-09-02 1993-04-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
US6319494B1 (en) 1990-12-14 2001-11-20 Cell Genesys, Inc. Chimeric chains for receptor-associated signal transduction pathways
IL104570A0 (en) 1992-03-18 1993-05-13 Yeda Res & Dev Chimeric genes and cells transformed therewith
US5830462A (en) 1993-02-12 1998-11-03 President & Fellows Of Harvard College Regulated transcription of targeted genes and other biological events
US5834266A (en) 1993-02-12 1998-11-10 President & Fellows Of Harvard College Regulated apoptosis
US5869337A (en) 1993-02-12 1999-02-09 President And Fellows Of Harvard College Regulated transcription of targeted genes and other biological events
US20030036654A1 (en) 1994-08-18 2003-02-20 Holt Dennis A. Synthetic multimerizing agents
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
KR20030032922A (ko) 2000-02-24 2003-04-26 싸이트 테라피스 인코포레이티드 세포의 동시 자극 및 농축
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US7446190B2 (en) * 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
EP1931712B1 (en) * 2005-08-26 2018-12-05 Roche Glycart AG Modified antigen binding molecules with altered cell signaling activity
US20100196336A1 (en) 2006-05-23 2010-08-05 Dongsu Park Modified dendritic cells having enhanced survival and immunogenicity and related compositions and methods
DK2516468T3 (en) * 2009-12-23 2016-05-23 Synimmune Gmbh ANTI-FLT3 ANTIBODIES AND METHODS FOR USING THESE
WO2011146862A1 (en) 2010-05-21 2011-11-24 Bellicum Pharmaceuticals, Inc. Methods for inducing selective apoptosis
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
WO2012103279A2 (en) 2011-01-26 2012-08-02 Ariad Pharmaceuticals, Incorporated Methods and compositions for the synthesis of multimerizing agents
CN110200997A (zh) 2011-03-23 2019-09-06 弗雷德哈钦森癌症研究中心 用于细胞免疫治疗的方法和组合物
CA3209571A1 (en) * 2012-03-23 2013-09-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-mesothelin chimeric antigen receptors
ES2868247T3 (es) 2013-02-15 2021-10-21 Univ California Receptor de antígeno quimérico y métodos de uso del mismo
US9944690B2 (en) 2013-03-14 2018-04-17 Bellicum Pharmaceuticals, Inc. Methods for controlling T cell proliferation
ES2910004T3 (es) 2013-07-29 2022-05-11 2Seventy Bio Inc Proteínas de señalización de múltiples partes y sus usos
JP6793902B2 (ja) 2013-12-20 2020-12-02 ノバルティス アーゲー 調節可能キメラ抗原受容体
AU2015218396A1 (en) 2014-02-14 2016-08-11 Bellicum Pharmaceuticals, Inc. Methods for activating T cells using an inducible chimeric polypeptide
CN106163547A (zh) * 2014-03-15 2016-11-23 诺华股份有限公司 使用嵌合抗原受体治疗癌症
TW201609812A (zh) * 2014-07-31 2016-03-16 安美基研究（慕尼黑）公司 最佳化之跨物種特異性雙特異性單鏈抗體構築體
ES2738705T3 (es) * 2014-09-19 2020-01-24 Hope City Linfocitos T de receptor de antígeno quimérico coestimulante que se dirigen a IL13R 2
TWI829617B (zh) * 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
WO2017173256A1 (en) * 2016-04-01 2017-10-05 Kite Pharma, Inc. Chimeric antigen and t cell receptors and methods of use

Also Published As

Publication number Publication date
MA44507A (fr) 2019-02-06
TN2018000337A1 (en) 2020-01-16
US20230124464A1 (en) 2023-04-20
NZ746925A (en) 2023-06-30
PH12018502118B1 (en) 2024-02-23
KR102694879B1 (ko) 2024-08-16
JP2024105337A (ja) 2024-08-06
MX2023013729A (es) 2023-11-28
CN109641956A (zh) 2019-04-16
IL262061B2 (en) 2023-03-01
PE20241061A1 (es) 2024-05-13
TWI776807B (zh) 2022-09-11
TW201803897A (zh) 2018-02-01
JP7561155B2 (ja) 2024-10-03
IL296966A (en) 2022-12-01
CA3019655A1 (en) 2017-10-05
CL2018002792A1 (es) 2019-04-26
AU2022200108A1 (en) 2022-02-03
WO2017173410A1 (en) 2017-10-05
BR112018070187A8 (pt) 2019-11-05
UA128326C2 (uk) 2024-06-12
MY201207A (en) 2024-02-09
CR20240116A (es) 2024-04-12
JP2022091793A (ja) 2022-06-21
SA518400154B1 (ar) 2022-11-09
TW202313669A (zh) 2023-04-01
AR127371A2 (es) 2024-01-17
AU2022200108B2 (en) 2024-09-19
EP3436479A1 (en) 2019-02-06
KR20190021203A (ko) 2019-03-05
PH12018502118A1 (en) 2019-07-08
KR102389096B1 (ko) 2022-04-25
BR112018070187A2 (pt) 2019-01-29
JP2019516352A (ja) 2019-06-20
IL262061A (en) 2018-11-29
AU2017240801A8 (en) 2018-11-29
SG11201808622SA (en) 2018-10-30
AU2017240801A1 (en) 2018-10-25
US20190183931A1 (en) 2019-06-20
WO2017173410A9 (en) 2017-12-14
PE20190201A1 (es) 2019-02-05
IL262061B (en) 2022-11-01
EA201892193A1 (ru) 2019-06-28
KR20220054453A (ko) 2022-05-02
AU2022200108C1 (en) 2025-07-31
AU2024278538A1 (en) 2025-01-30
CO2018011804A2 (es) 2019-02-08
CR20180518A (es) 2019-04-25
AR109626A1 (es) 2019-01-09

Similar Documents

Publication Publication Date Title
SG10201911963VA (en) Chimeric receptors to flt3 and methods of use thereof
SG10201912519VA (en) Chimeric receptors and methods of use thereof
IL320821A (en) Artificial immune receptors and methods of using them
ZA201705720B (en) Anti-dll3 chimeric antigen receptors and methods of use
IL277735A (en) DLL3 chimeric receptors and methods of using them
IL255336A0 (en) Chimeric antigen receptors and methods of using them
IL320860A (en) Chimeric antigen receptors and methods of using them
ZA201703471B (en) Anti-cldn chimeric antigen receptors and methods of use
ZA201605655B (en) Chimeric antigen receptors and methods of making
IL251868A0 (en) Anti-tim3 antibodies and methods of use
SG10201912489QA (en) Chimeric antigen and t cell receptors and methods of use
IL251970A0 (en) Anti-cd79b antibodies and methods of use
IL246736B (en) Anti-jagged1 antibodies and methods of use
SI3551209T1 (sl) Inzulin-FC fuzije in postopki uporabe
IL251165A0 (en) Anti-il-1beta antibodies and methods of their use
IL265438A (en) Chimeric antigen receptors and jewelry and methods of using them
IL251286A0 (en) Anti-pdgf-b antibodies and methods of use
GB201410250D0 (en) Improvements to nasal compositions and method of use thereof
SG11201605915WA (en) Furo-3-carboxamide derivatives and methods of use
GB201900228D0 (en) Glucagon analogs and methods of use thereof
HK40004166A (en) Chimeric receptors to flt3 and methods of use thereof
HK40092667A (en) Chimeric receptors and methods of use thereof
ZA201704416B (en) Heterocyclylalkyne derivatives and their use as modulators of mglur5 receptors